Pharmicell

Price Chart

Risk-Adjusted Performance

Pharmicell (005690) Price Performance

Pharmicell (005690) trades on KO in KRW. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at KRW18110.00, down 0.93% from the previous close.

Over the past year, 005690 has traded between a low of KRW10460.00 and a high of KRW19380.00. The stock has gained 56.1% over this period. It is currently 6.6% below its 52-week high.

Pharmicell has a market capitalization of $1.09T, with a price-to-earnings ratio of 27.02 and a dividend yield of 0.25%.

About Pharmicell

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC to treat hepatic insufficiency; Cellgram_ED for treating impotence; and Hearticellgram_AMI, a cardiac disease drug. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, a cell culture medium; and PharmiSTEM culture medium for mesenchymal stem cells, as well as clinical development and commercialization services for new drugs. Further, it operates stem cell bank under Twelve brand name; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.

Compare Pharmicell

Side-by-side comparison against top Healthcare peers.